Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

  • Technology appraisal guidance
  • TA258
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Guidance into practice